Treatment Advice Letter

Attach patient identification Sticker Title: First name:	GP's Details: Name: Practice:
Surname: Patient's Address:	Known Allergies:
D.o.b:	Date:

Dear Doctor,

Your patient has been diagnosed with Chronic ThromboEmbolic Pulmonary Hypertension (CTEPH) at the Sheffield Pulmonary Vascular Disease Unit and prescribed riociguat tablets.

Riociguat is a Soluble Guanylate Cyclase Stimulator (SGCS) which works for CTEPH by relaxing smooth muscle and subsequent vasodilatation though enhancing the action of cyclic GMP. Riociguat is the first licensed treatment for CTEPH and is endorsed by the UK National Commissioning Policy.

The treatment has already been initiated. Written information on how to take the tablets has been provided and counselling given at the hospital. Please refer to the Summary of Product Characteristics (SPC) for information on potential undesirable effects and drug interactions, before prescribing other medications to your patient.

This medication is funded by NHS England and is prescribed by the Sheffield Pulmonary Vascular Disease Unit. You should not be asked for prescriptions for this medication as the patient will be delivered all supplies and ancillaries by our Homecare Partners, Healthcare at Home (0870 600 1540) or Polar Speed (01525 276770). You are advised where possible, to insert this drug onto GP repeat prescribing systems so as to highlight any potentially harmful drug interactions e.g. PDE-5 inhibitors and nitrates. There is a useful reminder on how to do this for GP practices on the intranet.

We will write to you again if treatment with riociguat is stopped so that this can be removed from the patient's record.

If you have any queries regarding this or any aspect of their treatment, please do not hesitate to contact me on 0114 271 3259 or neil.hamilton@nhs.net.

Yours faithfully

sheffield pulmonary vascular disease unit

a nationally designated specialist centre

Neil Hamilton Pulmonary Vascular Disease Unit Pharmacist